Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $3.83 Average PT from Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received an average recommendation of “Hold” from the seven research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $3.8333.

A number of research firms recently commented on SGMO. Barclays reiterated an “equal weight” rating and set a $1.00 price objective (down previously from $5.00) on shares of Sangamo Therapeutics in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sangamo Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Sangamo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday, September 4th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new position in shares of Sangamo Therapeutics during the 2nd quarter valued at approximately $28,000. World Investment Advisors boosted its position in shares of Sangamo Therapeutics by 88.5% in the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 20,000 shares during the period. Cerity Partners LLC increased its stake in shares of Sangamo Therapeutics by 439.2% in the first quarter. Cerity Partners LLC now owns 55,000 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 44,800 shares in the last quarter. Caption Management LLC purchased a new stake in shares of Sangamo Therapeutics in the first quarter worth $37,000. Finally, XTX Topco Ltd bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at $41,000. Institutional investors own 56.92% of the company’s stock.

Sangamo Therapeutics Stock Down 0.4%

Shares of Sangamo Therapeutics stock opened at $0.42 on Friday. Sangamo Therapeutics has a twelve month low of $0.38 and a twelve month high of $2.84. The company’s 50 day moving average is $0.58 and its 200 day moving average is $0.54. The company has a market cap of $139.68 million, a price-to-earnings ratio of -1.43 and a beta of 1.25.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.08). The company had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $34.40 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. Sell-side analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.